Updated on 2024/12/04

写真a

 
YOSHINO Seiko
 
Organization
Graduate School of Medicine Center for Research of Laboratory Animals and Medical Research Engineering Division for Advanced Medical Research Assistant Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Assistant Professor

Degree 1

  1. 博士(生命科学) ( 2013.3   東京大学 ) 

 

Papers 12

  1. Rapid increase of C/EBPα p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1-expressing AML Reviewed

    Sunami Y, Yoshino S, Yamazaki Y, Iwamoto T, Nakamura T.

    Leukemia     2024.10

     More details

  2. Distinct microRNA signature and suppression of ZFP36L1 define ASCL1-positive lung adenocarcinoma. Reviewed

    Enokido T, Horie M, Yoshino S, Suzuki HI, Matsuki R, Brunnström H, Micke P, Nagase T, Saito A, Miyashita N

    Molecular cancer research : MCR     2023.10

     More details

    Language:English  

    DOI: 10.1158/1541-7786.MCR-23-0229

    PubMed

  3. Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis Reviewed

    Kitai Hiroki, Kato Noritoshi, Ogami Koichi, Komatsu Shintaro, Watanabe Yu, Yoshino Seiko, Koshi Eri, Tsubota Shoma, Funahashi Yoshio, Maeda Takahiro, Furuhashi Kazuhiro, Ishimoto Takuji, Kosugi Tomoki, Maruyama Shoichi, Kadomatsu Kenji, Suzuki Hiroshi I

    BMC BIOLOGY   Vol. 20 ( 1 ) page: 248   2022.11

     More details

    Language:English   Publisher:BMC Biology  

    Background: Combinatorial gene regulation by multiple microRNAs (miRNAs) is widespread and closely spaced target sites often act cooperatively to achieve stronger repression (“neighborhood” miRNA cotargeting). While miRNA cotarget sites are suggested to be more conserved and implicated in developmental control, the pathological significance of miRNA cotargeting remains elusive. Results: Here, we report the pathogenic impacts of combinatorial miRNA regulation on inflammation in systemic lupus erythematosus (SLE). In the SLE mouse model, we identified the downregulation of two miRNAs, miR-128 and miR-148a, by TLR7 stimulation in plasmacytoid dendritic cells. Functional analyses using human cell lines demonstrated that miR-128 and miR-148a additively target KLF4 via extensively overlapping target sites (“seed overlap” miRNA cotargeting) and suppress the inflammatory responses. At the transcriptome level, “seed overlap” miRNA cotargeting increases susceptibility to downregulation by two miRNAs, consistent with additive but not cooperative recruitment of two miRNAs. Systematic characterization further revealed that extensive “seed overlap” is a prevalent feature among broadly conserved miRNAs. Highly conserved target sites of broadly conserved miRNAs are largely divided into two classes—those conserved among eutherian mammals and from human to Coelacanth, and the latter, including KLF4-cotargeting sites, has a stronger association with both “seed overlap” and “neighborhood” miRNA cotargeting. Furthermore, a deeply conserved miRNA target class has a higher probability of haplo-insufficient genes. Conclusions: Our study collectively suggests the complexity of distinct modes of miRNA cotargeting and the importance of their perturbations in human diseases.

    DOI: 10.1186/s12915-022-01447-4

    Web of Science

    Scopus

    PubMed

  4. The molecular understanding of super-enhancer dysregulation in cancer Reviewed

    Yoshino Seiko, Suzuki Hiroshi I.

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 84 ( 2 ) page: 216 - 229   2022.5

     More details

    Authorship:Lead author   Language:English   Publisher:Nagoya Journal of Medical Science  

    Abnormalities in the regulation of gene expression are associated with various pathological conditions. Among the distal regulatory elements in the genome, the activation of target genes by enhancers plays a central role in the formation of cell type–specific gene expression patterns. Super-enhancers are a subclass of enhancers that frequently contain multiple enhancer-like elements and are characterized by dense binding of master transcription factors and Mediator complexes and high signals of active histone marks. Superenhancers have been studied in detail as important regulatory regions that control cell identity and contribute to the pathogenesis of diverse diseases. In cancer, super-enhancers have multifaceted roles by activating various oncogenes and other cancer-related genes and shaping characteristic gene expression patterns in cancer cells. Alterations in super-enhancer activities in cancer involve multiple mechanisms, including the dysregulation of transcription factors and the super-enhancer–associated genomic abnormalities. The study of super-enhancers could contribute to the identification of effective biomarkers and the development of cancer therapeutics targeting transcriptional addiction. In this review, we summarize the roles of super-enhancers in cancer biology, with a particular focus on hematopoietic malignancies, in which multiple super-enhancer alteration mechanisms have been reported.

    DOI: 10.18999/nagjms.84.2.216

    Web of Science

    Scopus

    PubMed

  5. BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes. Reviewed

    Sunami Y, Yokoyama T, Yoshino S, Takahara T, Yamazaki Y, Harada H, Nakamura T

    Blood advances   Vol. 6 ( 6 ) page: 1827 - 1843   2022.3

     More details

    Language:English  

    DOI: 10.1182/bloodadvances.2021004558

    PubMed

  6. Trib1 promotes the development of acute myeloid leukemia in a Ts1Cje mouse model of Down syndrome. Reviewed

    Yoshino S, Tanaka M, Sunami Y, Takahara T, Yamazaki Y, Homme M, Niibori-Nambu A, Osato M, Minami T, Ishihara K, Nakamura T

    Leukemia   Vol. 36 ( 2 ) page: 558 - 561   2022.2

     More details

    Authorship:Lead author   Language:English  

    DOI: 10.1038/s41375-021-01384-1

    PubMed

  7. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9. Reviewed

    Yoshino S, Yokoyama T, Sunami Y, Takahara T, Nakamura A, Yamazaki Y, Tsutsumi S, Aburatani H, Nakamura T

    Blood   Vol. 137 ( 1 ) page: 75 - 88   2021.1

     More details

    Authorship:Lead author   Language:English  

    DOI: 10.1182/blood.2019004586

    PubMed

  8. EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells. Reviewed International journal

    Seiko Yoshino, Yusuke Matsui, Yuya Fukui, Masahide Seki, Kiyoshi Yamaguchi, Akane Kanamori, Yurika Saitoh, Teppei Shimamura, Yutaka Suzuki, Yoichi Furukawa, Shuichi Kaneko, Motoharu Seiki, Yoshinori Murakami, Jun-Ichiro Inoue, Takeharu Sakamoto

    Scientific reports   Vol. 10 ( 1 ) page: 9275 - 9275   2020.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Cancer cells adapt to various stress conditions by optimizing gene expression profiles via transcriptional and translational regulation. However, whether and how EXOSC9, a component of the RNA exosome complex, regulates adaptation to stress conditions and tumorigenicity in cancer cells remain unclear. Here, we examined the effects of EXOSC9 depletion on cancer cell growth under various stress conditions. EXOSC9 depletion attenuated growth and survival under various stress conditions in cancer cells. Interestingly, this also decreased the number of P-bodies, which are messenger ribonucleoprotein particles (mRNPs) required for stress adaptation. Meanwhile, EXOSC2/EXOSC4 depletion also attenuated P-body formation and stress resistance with decreased EXOSC9 protein. EXOSC9-mediated stress resistance and P-body formation were found to depend on the intact RNA-binding motif of this protein. Further, RNA-seq analyses identified 343 EXOSC9-target genes, among which, APOBEC3G contributed to defects in stress resistance and P-body formation in MDA-MB-231 cells. Finally, EXOSC9 also promoted xenografted tumor growth of MDA-MB-231 cells in an intact RNA-binding motif-dependent manner. Database analyses further showed that higher EXOSC9 activity, estimated based on the expression of 343 target genes, was correlated with poorer prognosis in some cancer patients. Thus, drugs targeting activity of the RNA exosome complex or EXOSC9 might be useful for cancer treatment.

    DOI: 10.1038/s41598-020-66455-2

    Web of Science

    Scopus

    PubMed

  9. NECAB3 Promotes Activation of Hypoxia-inducible factor-1 during Normoxia and Enhances Tumourigenicity of Cancer Cells. Reviewed International journal

    Hiroki J Nakaoka, Toshiro Hara, Seiko Yoshino, Akane Kanamori, Yusuke Matsui, Teppei Shimamura, Hiroshi Sato, Yoshinori Murakami, Motoharu Seiki, Takeharu Sakamoto

    Scientific reports   Vol. 6   page: 22784 - 22784   2016.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Unlike most cells, cancer cells activate hypoxia inducible factor-1 (HIF-1) to use glycolysis even at normal oxygen levels, or normoxia. Therefore, HIF-1 is an attractive target in cancer therapy. However, the regulation of HIF-1 during normoxia is not well characterised, although Mint3 was recently found to activate HIF-1 in cancer cells and macrophages by suppressing the HIF-1 inhibitor, factor inhibiting HIF-1 (FIH-1). In this study, we analysed Mint3-binding proteins to investigate the mechanism by which Mint3 regulates HIF-1. Yeast two-hybrid screening using Mint3 as bait identified N-terminal EF-hand calcium binding protein 3 (NECAB3) as a novel factor regulating HIF-1 activity via Mint3. NECAB3 bound to the phosphotyrosine-binding domain of Mint3, formed a ternary complex with Mint3 and FIH-1, and co-localised with Mint3 at the Golgi apparatus. Depletion of NECAB3 decreased the expression of HIF-1 target genes and reduced glycolysis in normoxic cancer cells. NECAB3 mutants that binds Mint3 but lacks an intact monooxygenase domain also inhibited HIF-1 activation. Inhibition of NECAB3 in cancer cells by either expressing shRNAs or generating a dominant negative mutant reduced tumourigenicity. Taken together, the data indicate that NECAB3 is a promising new target for cancer therapy.

    DOI: 10.1038/srep22784

    Web of Science

    Scopus

    PubMed

  10. The ERK signaling target RNF126 regulates anoikis resistance in cancer cells by changing the mitochondrial metabolic flux. Reviewed International journal

    Seiko Yoshino, Toshiro Hara, Hiroki J Nakaoka, Akane Kanamori, Yoshinori Murakami, Motoharu Seiki, Takeharu Sakamoto

    Cell discovery   Vol. 2   page: 16019 - 16019   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Loss of anchorage to the extracellular matrix leads to apoptosis (anoikis) in normal cells, but cancerous cells are usually resistant to such stress. Here we report the pivotal role of an E3 ubiquitin ligase, ring-finger protein 126 (RNF126), in the resistance of cancer cells to the stress associated with non-adherent conditions. Non-adherent cancer cells exhibited increased flux through the tricarboxylic acid cycle via increased conversion of pyruvate to acetyl-CoA. RNF126 was found to act as a ubiquitin ligase for pyruvate dehydrogenase kinases (PDKs), resulting in their proteasomal degradation. This decrease in PDK levels allowed pyruvate dehydrogenases to catalyze the conversion of pyruvate to acetyl-CoA. Moreover, depletion of RNF126 or increased expression of PDK1 in cancer cells suppressed colony formation in soft agar as well as tumorigenicity in mice. RNF126 expression in cancer cells was found to be under the control of the extracellular signal-regulated kinase signaling pathway, which is essential for anoikis resistance. Thus, RNF126 is an attractive molecule for treating cancer by selectively targeting anchorage-independent growth.

    DOI: 10.1038/celldisc.2016.19

    PubMed

  11. Hypoxia-inducible factor 1 regulation through cross talk between mTOR and MT1-MMP. Reviewed International journal

    Takeharu Sakamoto, Jane S Weng, Toshiro Hara, Seiko Yoshino, Hiroko Kozuka-Hata, Masaaki Oyama, Motoharu Seiki

    Molecular and cellular biology   Vol. 34 ( 1 ) page: 30 - 42   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hypoxia-inducible factor 1 (HIF-1) plays a key role in the cellular adaptation to hypoxia. Although HIF-1 is usually strongly suppressed by posttranslational mechanisms during normoxia, HIF-1 is active and enhances tumorigenicity in malignant tumor cells that express the membrane protease MT1-MMP. The cytoplasmic tail of MT1-MMP, which can bind a HIF-1 suppressor protein called factor inhibiting HIF-1 (FIH-1), promotes inhibition of FIH-1 by Mint3 during normoxia. To explore possible links between HIF-1 activation by MT1-MMP/Mint3 and tumor growth signals, we surveyed a panel of 252 signaling inhibitors. The mTOR inhibitor rapamycin was identified as a possible modulator, and it inhibited the mTOR-dependent phosphorylation of Mint3 that is required for FIH-1 inhibition. A mutant Mint3 protein that cannot be phosphorylated exhibited a reduced ability to inhibit FIH-1 and promoted tumor formation in mice. These data suggest a novel molecular link between the important hub proteins MT1-MMP and mTOR that contributes to tumor malignancy.

    DOI: 10.1128/MCB.01169-13

    PubMed

  12. Genetic screening of new genes responsible for cellular adaptation to hypoxia using a genome-wide shRNA library. Reviewed International journal

    Seiko Yoshino, Toshiro Hara, Jane S Weng, Yuka Takahashi, Motoharu Seiki, Takeharu Sakamoto

    PloS one   Vol. 7 ( 4 ) page: e35590   2012

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Oxygen is a vital requirement for multi-cellular organisms to generate energy and cells have developed multiple compensatory mechanisms to adapt to stressful hypoxic conditions. Such adaptive mechanisms are intricately interconnected with other signaling pathways that regulate cellular functions such as cell growth. However, our understanding of the overall system governing the cellular response to the availability of oxygen remains limited. To identify new genes involved in the response to hypoxic stress, we have performed a genome-wide gene knockdown analysis in human lung carcinoma PC8 cells using an shRNA library carried by a lentiviral vector. The knockdown analysis was performed under both normoxic and hypoxic conditions to identify shRNA sequences enriched or lost in the resulting selected cell populations. Consequently, we identified 56 candidate genes that might contribute to the cellular response to hypoxia. Subsequent individual knockdown of each gene demonstrated that 13 of these have a significant effect upon oxygen-sensitive cell growth. The identification of BCL2L1, which encodes a Bcl-2 family protein that plays a role in cell survival by preventing apoptosis, validates the successful design of our screen. The other selected genes have not previously been directly implicated in the cellular response to hypoxia. Interestingly, hypoxia did not directly enhance the expression of any of the identified genes, suggesting that we have identified a new class of genes that have been missed by conventional gene expression analyses to identify hypoxia response genes. Thus, our genetic screening method using a genome-wide shRNA library and the newly-identified genes represent useful tools to analyze the cellular systems that respond to hypoxic stress.

    DOI: 10.1371/journal.pone.0035590

    PubMed

▼display all

MISC 8

  1. 生体分子凝集体と染色体外環状DNA (Bio Clinica 2023年7月号転載)

    芳野 聖子、鈴木 洋

    Bio Clinica臨時増刊号   Vol. 39 ( 14 ) page: 56 - 61   2024.12

     More details

    Authorship:Lead author  

  2. 生体分子凝集体と染色体外環状DNA (Bio Clinica 2023年7月号転載)

    芳野 聖子、鈴木 洋

    月刊「細胞」臨時増刊号   Vol. 56 ( 14 ) page: 58 - 62   2024.12

     More details

    Authorship:Lead author  

  3. 生体分子凝集体と染色体外環状DNA (Bio Clinica 2023年7月号転載)

    芳野 聖子, 鈴木 洋

    月刊細胞   Vol. 56 ( 6 ) page: 43 - 47   2024.6

     More details

    Authorship:Lead author  

  4. 生体分子凝集体と染色体外環状DNA

    芳野 聖子、鈴木 洋

    Bio Clinica   Vol. 38 ( 7 ) page: 66 - 71   2023.7

     More details

    Authorship:Lead author  

  5. 第2部5章 デジタルPCRによるmiRNAの測定

    芳野 聖子, 小松 真太郎, 鈴木 洋

    実験医学部冊「リアルタイム・デジタルPCR実験スタンダード」     page: 258 - 264   2022.2

  6. Trib1によるHoxa9転写制御の修飾とAML発症

    中村 卓郎, 芳野 聖子

    血液内科   Vol. 83 ( 1 ) page: 115 - 120   2021.7

     More details

    Language:Japanese   Publisher:(有)科学評論社  

  7. Pseudokinase TRIB1による骨髄系腫瘍の発症と進展機構

    芳野 聖子, 中村 卓郎

    血液内科   Vol. 82 ( 4 ) page: 573 - 579   2021.4

     More details

    Authorship:Lead author   Publisher:(有)科学評論社  

  8. Introduce My Article

    芳野 聖子, 中村 卓郎

    臨床血液   Vol. 61 ( 11 ) page: 1634   2020.11

     More details

    Authorship:Lead author  

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 6

  1. 染色体外環状DNA陽性がんにおける新規生存必須遺伝子の機能解明

    2024 - 2028

    武田科学振興財団医学系 研究助成(がん領域・基礎) 

    芳野聖子

      More details

    Authorship:Principal investigator 

  2. 染色体外環状DNAによるがん悪性化進展機構の解明と治療標的としての可能性

    Grant number:22K07210  2022.4 - 2025.3

    科学研究費助成事業  基盤研究(C)

    芳野 聖子

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    近年、がん細胞には染色体外環状DNA(eccDNA)が広範に存在することが報告され、がんの増殖や不均一性との関連が示唆されている。重要なことに、eccDNAを介したがん遺伝子の増幅は、正常組織ではほとんど見られない。一方で、様々ながん種におけるeccDNAの構造の違いやがん細胞の生存・増殖への影響については、依然として不明な点が多く存在する。本研究では、eccDNAを様々ながん種で包括的に解析し、がん細胞における生物学的特性を解明することで、がん治療標的としての可能性を明らかにするとともに、がん特異的な治療薬の同定に繋げることを目的とする。

  3. Extrachromosomal circular DNAを標的にした新規がん治療薬の探索と同定

    2022

    日比野基金医学研究助成 

    芳野 聖子

      More details

    Authorship:Principal investigator 

  4. 公益財団法人 上原記念生命科学財団 研究奨励金

    2021

    AMLにおけるTRIB1のスーパーエンハンサー制御

    芳野 聖子

      More details

    Authorship:Principal investigator 

  5. AML malignant mechanism by enhancer reprogramming of Trib1

    Grant number:20K16318  2020.4 - 2022.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    Yoshino Seiko

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    Down syndrome is caused by trisomy of chromosome 21 and is the most frequent genetic disorder arising from chromosomal abnormality. Trib1 pseudokinase acts as a collaborator of Hoxa9/Meis1 in leukemogenesis, inducing enhancement of MAPK signals and degradation of C/EBPa. Ts1Cje, a mouse model for DS, is trisomic for approximately 70 genes of human chromosome 21. Here, we aimed to introduce Trib1 in Ts1Cje mice to examine whether the expression of Trib1 cooperates with trisomy 21 in the development of leukemia. Expression of both wild type and R107L Trib1 in Ts1Cje bone marrow cells significantly accelerated disease onset of AML. Additionaly, AML cell lines expressing wild type Trib1 were generated in Ts1Cje and B6 bone marrow cells. Gene set enrichment analysis showed the enrichment of the target gene sets of the posterior Hoxa cluster. These data strongly suggest the importance of TRIB1-associated signaling in the transformation and/or malignant progression of DS-related leukemia.

  6. Trib1 functions as a critical epigenetic regulator in AML

    Grant number:18K15227  2018.4 - 2020.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists  Grant-in-Aid for Early-Career Scientists

    Yoshino Seiko

      More details

    Authorship:Principal investigator 

    The pseudokinase Trib1 functions as a myeloid oncogene that recruits the ubiquitin ligase COP1 to C/EBPα and interacts with MEK1 to enhance ERK phosphorylation. Close genetic interaction between Trib1 and Hoxa9 have been observed in myeloid leukemogenesis. Herein, we provide evidence that Trib1 modulates Hoxa9-associated super-enhancers. ChIP-seq analysis identified increased H3K27Ac signals at super-enhancers of the Erg, Spns2, Rgl1, and Pik3cd loci, as well as increased mRNA expression. Modification of super-enhancer activity was mostly achieved via p42-specific degradation of C/EBPα by Trib1. Silencing of Erg abrogated the growth advantage acquired by Trib1 overexpression, indicating that Erg is a critical downstream target. Moreover, treatment with a BRD4 inhibitor JQ1 showed growth inhibition in a Trib1/Erg-dependent manner both in vitro and in vivo. Collectively, our study demonstrates a novel mechanism of Trib1 in modulations of chromatin and Hoxa9-driven transcription.

▼display all